On Oct 31, major Wall Street analysts update their ratings for $Arvinas (ARVN.US)$, with price targets ranging from $40 to $87.
Barclays analyst Peter Lawson maintains with a buy rating, and maintains the target price at $48.
Wells Fargo analyst Derek Archila maintains with a buy rating, and maintains the target price at $60.
TD Cowen analyst Tyler Van Buren maintains with a buy rating.
Oppenheimer analyst Matthew Biegler maintains with a buy rating, and maintains the target price at $40.
Truist Financial analyst Srikripa Devarakonda maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Arvinas (ARVN.US)$'s main analysts recently are as follows:
The analyst noted that Arvinas' initial quarterly call was opportune, providing the company the platform to strategically position itself prior to a series of significant forthcoming events. The analyst expressed concerns that the TACTIVE-U data may not appear as compelling as the previous vepdeg + palbo results showcased at SABCS the prior year, suggesting that the combination may have set an unreasonably high benchmark due to drug-drug interaction (DDI) effects. A comparison to the EMBER-3 outcomes, anticipated to also be presented at SABCS, might be more appropriate. Further, the analyst mentioned that the EMBER-3 results could potentially affect the interpretation of the VERITAC-2 trial data, particularly if efficacy is confined to ESR1-mutants. Despite these considerations, the analyst maintains that VERITAC-2 could still pave the way for vepdeg's market entry, albeit with possibly a narrower commercial scope.
Here are the latest investment ratings and price targets for $Arvinas (ARVN.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月31日，多家华尔街大行更新了$Arvinas (ARVN.US)$的评级，目标价介于40美元至87美元。
巴克莱银行分析师Peter Lawson维持买入评级，维持目标价48美元。
富国集团分析师Derek Archila维持买入评级，维持目标价60美元。
TD Cowen分析师Tyler Van Buren维持买入评级。
奥本海默控股分析师Matthew Biegler维持买入评级，维持目标价40美元。
储亿银行分析师Srikripa Devarakonda维持买入评级。
此外，综合报道，$Arvinas (ARVN.US)$近期主要分析师观点如下：
以下为今日6位分析师对$Arvinas (ARVN.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
